Merotocin

Merotocin
Clinical data
Other names	N-(4-Sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-N-[(4-fluorophenyl)methyl]glycyl-L-leucylglycinamide cyclic (1-5)-thioether
ATC code	None;
Identifiers
	IUPAC name (3R,6S,9S,12S,15S)-6-(2-Amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide;
CAS Number	1190083-57-8;
PubChem CID	76073634;
ChemSpider	34994563;
UNII	UW3ON116CO;
Chemical and physical data
Formula	C48H68FN11O12S
Molar mass	1042.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)Cc2ccc(cc2)O)C(=O)N(Cc3ccc(cc3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N;
	InChI InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27-,32-,33-,34-,35-,36-,42-/m0/s1; Key:PVVHQWISMVJHFK-NIFJBHDKSA-N;

Merotocin (INN) (developmental code name FE-202767), also known as carba-1-(4-FBzlGly⁷)dOT, is a peptidic agonist of the oxytocin receptor that was derived from oxytocin.^[1]^[2]^[3] It is under development by Ferring Pharmaceuticals for the treatment of preterm mothers with lactation failure requiring lactation support, and is in phase II clinical trials for this indication.^[3] Merotocin is potent (EC₅₀ < 0.1 nM) and highly selective (>1000-fold over the related vasopressin receptors).

References

^ Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G (2012). "Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics". Journal of Neuroendocrinology. 24 (4): 609–28. doi:10.1111/j.1365-2826.2012.02303.x. PMC 3490377. PMID 22375852.
^ Yang Y, Li H, Ward R, Gao L, Wei JF, Xu TR (2014). "Novel oxytocin receptor agonists and antagonists: a patent review (2002 - 2013)". Expert Opinion on Therapeutic Patents. 24 (1): 29–46. doi:10.1517/13543776.2014.845168. PMID 24094047. S2CID 10584554.
^ ^a ^b Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJ, Schteingart CD (2014). "New, potent, and selective peptidic oxytocin receptor agonists". J. Med. Chem. 57 (12): 5306–17. doi:10.1021/jm500365s. PMID 24874785.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.